Literature DB >> 7867564

Ligand requirements of the human corticotropin-releasing factor-binding protein.

S W Sutton1, D P Behan, S L Lahrichi, R Kaiser, A Corrigan, P Lowry, E Potter, M H Perrin, J Rivier, W W Vale.   

Abstract

CRF-binding protein (CRF-BP), identified as a 37-kilodalton human serum protein, binds human (h) CRF (Kd = 0.17 +/- 0.01 nM) and blocks hCRF's ability to stimulate ACTH release by pituitary cells in vitro. The present study examines ligand requirements of CRF-BP by testing the affinity of recombinant CRF-BP for synthetic analogs of CRF and peptides in the CRF family. The relative affinities of various fragments of hCRF or related peptides for CRF-BP indicate that residues 9-28 are crucial for ligand binding. CRF-BP binds human/rat CRF and urotensin-I with high affinity, sauvagine with moderate affinity, and ovine (o) CRF with low affinity. The marked difference in the affinity of CRF-BP for oCRF (Ki = 1100 +/- 97 nM) compared to hCRF (Ki = 0.17 +/- 0.01 nM), when considered with the importance of the central domain, suggests that amino acids 22, 23, and/or 25 are critical for binding. Altering oCRF residues 22, 23, or 25 individually or collectively to match those of hCRF increases the affinity of CRF-BP for these ligands; [Ala22, Arg23, Glu25]oCRF, in which all three of these central amino acids are substituted by their hCRF counterparts, binds CRF-BP with an affinity equal to that of hCRF. CRF-BP has differential affinities for CRF receptor antagonists, binding alpha-helical CRF-(9-41) with high affinity and [D-Phe12, Nle21,38]hCRF-(12-41) with low affinity. Thus, the structural requirements for binding to CRF-BP can clearly be distinguished from those for CRF receptor recognition of both agonists and antagonists. Peptides such as hCRF-(9-33), with low biological activity but which retain high affinity for the binding protein, can competitively override the effects of CRF-BP to block CRF-induced ACTH secretion, raising the possibility that whereas endogenous CRF-BP serves to limit the distribution or duration of action of CRF, specific pharmacological inhibitors of the ligand-binding protein interaction might be used to therapeutically elevate free CRF levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7867564     DOI: 10.1210/endo.136.3.7867564

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  26 in total

1.  Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor.

Authors:  M L Price; I Lucki
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Do centrally administered neuropeptides access cognate receptors?: an analysis in the central corticotropin-releasing factor system.

Authors:  J C Bittencourt; P E Sawchenko
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

3.  Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.

Authors:  K Lewis; C Li; M H Perrin; A Blount; K Kunitake; C Donaldson; J Vaughan; T M Reyes; J Gulyas; W Fischer; L Bilezikjian; J Rivier; P E Sawchenko; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

4.  Sex differences in corticotropin-releasing factor receptor-1 action within the dorsal raphe nucleus in stress responsivity.

Authors:  Alexis R Howerton; Alison V Roland; Jessica M Fluharty; Anikò Marshall; Alon Chen; Derek Daniels; Sheryl G Beck; Tracy L Bale
Journal:  Biol Psychiatry       Date:  2013-10-23       Impact factor: 13.382

5.  Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor.

Authors:  J Gulyas; C Rivier; M Perrin; S C Koerber; S Sutton; A Corrigan; S L Lahrichi; A G Craig; W Vale; J Rivier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

Review 6.  Corticotropin-releasing hormone-binding protein and stress: from invertebrates to humans.

Authors:  Kyle D Ketchesin; Gwen S Stinnett; Audrey F Seasholtz
Journal:  Stress       Date:  2017-05-18       Impact factor: 3.493

7.  Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling.

Authors:  A Rühmann; A K Köpke; F M Dautzenberg; J Spiess
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

8.  Corticotropin-releasing factor in the basolateral amygdala enhances memory consolidation via an interaction with the beta-adrenoceptor-cAMP pathway: dependence on glucocorticoid receptor activation.

Authors:  Benno Roozendaal; Gustav Schelling; James L McGaugh
Journal:  J Neurosci       Date:  2008-06-25       Impact factor: 6.167

9.  Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1.

Authors:  Mark O Huising; Joan M Vaughan; Shaili H Shah; Katherine L Grillot; Cynthia J Donaldson; Jean Rivier; Gert Flik; Wylie W Vale
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

10.  Effects of acidic-astressin and ovine-CRF microinfusions into the ventral hippocampus on defensive behaviors in rats.

Authors:  Nathan S Pentkowski; Yoav Litvin; D Caroline Blanchard; Amy Vasconcellos; Lanikea B King; Robert J Blanchard
Journal:  Horm Behav       Date:  2009-03-06       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.